La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

UCB Résultats passés

Passé contrôle des critères 1/6

Les bénéfices de UCB ont diminué à un taux annuel moyen de -17.4%, tandis que le secteur Pharmaceuticals a vu ses bénéfices augmenter de en à 8.9% par an. Les revenus ont augmenté de en à un taux moyen de 1.4% par an. Le rendement des capitaux propres de UCB est 2.7% et ses marges nettes sont de 4.4%.

Informations clés

-17.4%

Taux de croissance des bénéfices

-17.6%

Taux de croissance du BPA

Pharmaceuticals Croissance de l'industrie	12.4%
Taux de croissance des recettes	1.4%
Rendement des fonds propres	2.7%
Marge nette	4.4%
Prochaine mise à jour des résultats	27 Feb 2025

Mises à jour récentes des performances passées

Recent updates

Analysts Have Made A Financial Statement On UCB SA's (EBR:UCB) Half-Yearly Report

Jul 28

Investors Still Waiting For A Pull Back In UCB SA (EBR:UCB)

Jul 15

Shareholders Will Probably Not Have Any Issues With UCB SA's (EBR:UCB) CEO Compensation

Apr 19

UCB SA Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Jul 31

Is UCB (EBR:UCB) A Risky Investment?

Jun 21

UCB SA's (EBR:UCB) Intrinsic Value Is Potentially 96% Above Its Share Price

May 13

Is UCB (EBR:UCB) Using Too Much Debt?

Mar 18

Will Weakness in UCB SA's (EBR:UCB) Stock Prove Temporary Given Strong Fundamentals?

Feb 28

Ventilation des recettes et des dépenses

Comment UCB gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.

Historique des gains et des recettes

ENXTBR:UCB Recettes, dépenses et bénéfices (EUR Millions )
Date	Recettes	Les revenus	Dépenses G+A	Dépenses de R&D
30 Jun 24	5,454	240	2,033	1,660
31 Mar 24	5,318	292	1,929	1,645
31 Dec 23	5,182	343	1,824	1,630
30 Jun 23	5,111	332	1,726	1,631
31 Mar 23	5,279	376	1,720	1,651
31 Dec 22	5,447	420	1,714	1,670
30 Jun 22	5,854	887	1,695	1,674
31 Mar 22	5,816	971	1,625	1,652
31 Dec 21	5,777	1,055	1,554	1,629
30 Sep 21	5,647	996	1,506	1,631
30 Jun 21	5,517	936	1,458	1,633
31 Mar 21	5,432	834	1,438	1,601
31 Dec 20	5,347	732	1,417	1,569
30 Jun 20	5,198	743	1,368	1,393
31 Mar 20	5,056	767	1,336	1,333
31 Dec 19	4,913	790	1,303	1,272
30 Jun 19	4,686	652	1,212	1,229
31 Mar 19	4,659	722	1,178	1,195
31 Dec 18	4,632	792	1,144	1,161
30 Jun 18	4,569	872	1,105	1,083
31 Mar 18	4,522	812	1,119	1,070
31 Dec 17	4,474	752	1,132	1,057
30 Sep 17	4,400	708	1,138	1,047
30 Jun 17	4,325	664	1,144	1,036
31 Mar 17	4,236	604	1,133	1,028
31 Dec 16	4,147	543	1,122	1,020
30 Sep 16	4,051	439	1,111	1,022
30 Jun 16	3,955	334	1,099	1,023
31 Mar 16	3,916	299	1,098	1,030
31 Dec 15	3,876	264	1,096	1,037
30 Sep 15	3,773	266	1,069	999
30 Jun 15	3,670	268	1,042	961
31 Mar 15	3,507	192	1,011	945
31 Dec 14	3,344	115	980	928
30 Sep 14	3,206	114	963	905
30 Jun 14	3,067	112	946	881
31 Mar 14	3,100	97	971	884
31 Dec 13	3,133	82	996	886

Des revenus de qualité: UCB a des bénéfices de haute qualité.

Augmentation de la marge bénéficiaire: Les marges bénéficiaires nettes actuelles de UCB (4.4%) sont inférieures à celles de l'année dernière (6.5%).

Analyse des flux de trésorerie disponibles par rapport aux bénéfices

Analyse de la croissance passée des bénéfices

Tendance des revenus: Les bénéfices de UCB ont diminué de 17.4% par an au cours des 5 dernières années.

Accélération de la croissance: UCB a connu une croissance négative de ses bénéfices au cours de l'année écoulée, elle ne peut donc pas être comparée à sa moyenne sur 5 ans.

Bénéfices par rapport au secteur d'activité: UCB a enregistré une croissance négative de ses bénéfices ( -27.7% ) au cours de l'année écoulée, ce qui rend difficile la comparaison avec la moyenne du secteur Pharmaceuticals ( 4.5% ).

Rendement des fonds propres

ROE élevé: Le retour sur capitaux propres de UCB ( 2.7% ) est considéré comme faible.

UCB Résultats passés

Passé contrôle des critères 1/6

Informations clés

Mises à jour récentes des performances passées

First half 2024 earnings released: EPS: €1.10 (vs €1.64 in 1H 2023)

UCB SA to Report First Half, 2024 Results on Jul 25, 2024

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

UCB SA to Report Fiscal Year 2023 Results on Feb 21, 2024

First half 2023 earnings released: EPS: €1.64 (vs €2.10 in 1H 2022)

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

Consensus EPS estimates increase by 14%

Price target increased by 8.5% to €153

Analysts Have Made A Financial Statement On UCB SA's (EBR:UCB) Half-Yearly Report

First half 2024 earnings released: EPS: €1.10 (vs €1.64 in 1H 2023)

Investors Still Waiting For A Pull Back In UCB SA (EBR:UCB)

Price target increased by 7.2% to €135

UCB Announces New CIMZIA® Data for Women Living with Chronic Rheumatic Diseases Throughout Pregnancy, and for People Living with Ra and High Rheumatoid Factor Levels

UCB SA, Annual General Meeting, Apr 24, 2025

Insufficient new directors

UCB SA to Report First Half, 2024 Results on Jul 25, 2024

Dividend of €0.95 announced

Shareholders Will Probably Not Have Any Issues With UCB SA's (EBR:UCB) CEO Compensation

Consensus EPS estimates increase by 18%

UCB Announces FDA Accepts Supplemental Biologics License Applications for Bimzelx

Is UCB (EBR:UCB) A Risky Investment?

UCB Announces 48-Week Phase 3 Analyses of Pooled Phase 3 Data from the BE HEARD I and BE HEARD II Studies

Price target increased by 9.4% to €111

Consensus EPS estimates fall by 14%

Earnings Tell The Story For UCB SA (EBR:UCB) As Its Stock Soars 26%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

UCB SA's (EBR:UCB) P/E Is On The Mark

UCB Presents New Data About the Real-World Experience of FINTEPLA® (Fenfluramine) and Rare Epilepsy Syndromes At 2023 American Epilepsy Society (AES) Annual Meeting

UCB SA Announces U.S. Availability of BIMZELX for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB to Present Post Hoc Analysis of the EXXELERATE Trial Evaluating the Efficacy of CIMZIA®? (Certolizumab Pegol) and Adalimumab in Patients with Rheumatoid Arthritis and High Rheumatoid Factor

UCB (EBR:UCB) Takes On Some Risk With Its Use Of Debt

UCB Presents Latest Data from Generalized Myasthenia Gravis Portfolio

UCB SA Announces Publication of NAYZILAM® (midazolam) Results in 'Epilepsy & Behavior' Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters

UCB Announces U.S. FDA Approves BIMZELX (Bimekizumab-Bkzx) for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB Announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the Treatment of Adults with Generalized Myasthenia Gravis

UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023

UCB Announces Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa

Is UCB (EBR:UCB) Using Too Much Debt?

UCB SA to Report Fiscal Year 2023 Results on Feb 21, 2024

First half 2023 earnings released: EPS: €1.64 (vs €2.10 in 1H 2022)

Ucb Announces That Rystiggo Is Commercially Available for the Treatment of Adult Patients in the U.S. with Generalized Myasthenia Gravis (Gmg) Who Are Anti-Acetylcholine Receptor (Achr) or Anti-Muscle-Specific Tyrosine Kinase (Musk) Antibody Positive

UCB Announces Resignation of Head of Neurology Solutions Charl Van Zyl

Are Investors Undervaluing UCB SA (EBR:UCB) By 48%?

Upcoming dividend of €0.93 per share at 1.5% yield

UCB's (EBR:UCB) Upcoming Dividend Will Be Larger Than Last Year's

Does UCB (EBR:UCB) Have A Healthy Balance Sheet?

Consensus EPS estimates fall by 17%

Consensus EPS estimates fall by 16%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

UCB Announces Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

UCB SA to Report Fiscal Year 2022 Results on Feb 22, 2023

UCB Announces Rozanolixizumab BLA for the Treatment of Generalized Myasthenia Gravis Filed with U.S. FDA and Designated for Priority Review

UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa

Here's Why UCB (EBR:UCB) Can Manage Its Debt Responsibly

UCB SA to Present Data At the American Epilepsy Society 76Th Annual Meeting 2022 Supporting A Decades-Long Commitment to Transforming Epilepsy Care

UCB Announces the Publication of Long-Term Open-Label Extension (OLE) Study Results of FINTEPLA® (Fenfluramine) CIV in Epilepsia

UCB Announces U.S. FDA Acceptance of New Drug Application and EMA MAA Validation for Zilucoplan for the Treatment of Generalized Myasthenia Gravis in Adult Patients

UCB Announces the First Presentation of Long-Term, 52-Week Data from Three Phase 3 Studies Evaluating the Efficacy and Safety of Bimekizumab in Adults with Active Psoriatic Arthritis

UCB Announces New Three-Year Results from the BE BRIGHT Open-Label Extension Study

These 4 Measures Indicate That UCB (EBR:UCB) Is Using Debt Reasonably Well

First half 2022 earnings released

Consensus forecasts updated

Consensus forecasts updated

Consensus forecasts updated

Consensus forecasts updated

Does UCB (EBR:UCB) Have A Healthy Balance Sheet?

UCB, Announces New 24-Week Data from Two Phase 3 Studies, Be Mobile 1 and Be Mobile 2

UCB SA Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to Be Presented At EULAR 2022

UCB SA, Annual General Meeting, Apr 27, 2023

UCB Presents Efficacy and Safety Results for Zilucoplan and Rozanolixizumab in Generalized Myasthenia Gravis

UCB Announces Jama Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of Fintepla® (Fenfluramine) Oral Solution in Lennox-Gastaut Syndrome

UCB (EBR:UCB) Is Paying Out A Larger Dividend Than Last Year

Upcoming dividend of €0.91 per share

UCB's (EBR:UCB) Upcoming Dividend Will Be Larger Than Last Year's

UCB SA Announces Oral Solution Civ Approves for Treatment of Seizures Associated with Lennox-Gastaut Syndrome